Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1274 studies found for:    "Macular Degeneration"
Show Display Options
Rank Status Study
21 Active, not recruiting A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration
Condition: Age-Related Macular Degeneration
Interventions: Drug: DE-120;   Drug: Aflibercept
22 Completed Oxidative Stress in Patients With Age-Related Macular Degeneration
Condition: Macular Degeneration
Intervention:
23 Completed The Optical Coherence Tomography in Age-Related Macular Degeneration Study: The OCT in AMD Study
Condition: Macular Degeneration
Intervention: Other: examination only
24 Unknown  Y402H Comlement Factor H Polymorphism and Age-Related Macular Degeneration in the Austrian Population
Condition: Age-Related Macular Degeneration
Intervention: Procedure: drawing blood
25 Recruiting Five-year Incidence of Age-related Macular Degeneration in the Central Region of Portugal
Condition: Age-Related Macular Degeneration
Intervention:
26 Completed WALTZ - Wet Age-Related Macular Degeneration (AMD) AL-39324 Treatment Examination
Condition: Age Related Macular Degeneration
Interventions: Drug: AL-39324 ophthalmic suspension;   Drug: Ranibizumab 10 mg/mL
27 Active, not recruiting Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD)
Condition: Age Related Macular Degeneration
Intervention: Drug: 3 dose cohorts gene therapy
28 Withdrawn Combination Therapy for Neovascular Age Related Macular Degeneration
Condition: Macular Degeneration
Intervention: Drug: intravitreal bevacizumab and triamcinolone acetonide
29 Completed Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration
Condition: Macular Degeneration
Intervention: Drug: Bevasiranib
30 Unknown  Rheohemapheresis and Lutein Supplementation in the Non-Exsudative Form of Age-Related Macular Degeneration
Condition: Age-related Macular Degeneration
Intervention:
31 Unknown  Intravitreal Bone Marrow-Derived Stem Cells in Patients With Macular Degeneration
Condition: Age Related Macular Degeneration and Stargartd
Intervention: Other: intravitreal injection of autologous bone marrow stem cells
32 Recruiting A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention: Drug: DE-122
33 Completed
Has Results
Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration
Condition: Macular Degeneration
Intervention: Drug: pegaptanib sodium
34 Completed Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration.
Condition: Macular Degeneration
Intervention: Biological: Ranibizumab
35 Completed
Has Results
Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration
Condition: Macular Degeneration
Intervention: Drug: Macugen
36 Active, not recruiting Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration
Condition: Macular Degeneration
Intervention:
37 Completed
Has Results
Lucentis in Advanced Macular Degeneration
Condition: Macular Degeneration
Intervention: Drug: ranibizumab
38 Completed Systemic Avastin Therapy in Age-Related Macular Degeneration
Condition: Macular Degeneration
Interventions: Drug: Bevacizumab;   Drug: Sodium Chloride
39 Completed Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan
Condition: Wet Macular Degeneration
Intervention: Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
40 Completed Celecoxib to Treat Macular Degeneration in Patients Receiving Photodynamic Therapy
Condition: Macular Degeneration
Intervention: Drug: Celecoxib

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.